Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC)

Che Kai Tsao, Matthew D. Galsky, Alexander C. Small, Tiffany Yee, William K. Oh

Research output: Contribution to journalReview articlepeer-review

49 Scopus citations


What's known on the subject? and What does the study add? Castration resistance has been appreciated for decades, and several mechanisms theorising on this effect have been proposed. A rich pipeline of novel agents, including abiraterone and MDV3100, have provided proof of principle that novel agents targeting the AR signalling pathway with superior selectivity and activity than predecessors have yielded significant clinical benefit for patients with metastatic castration-resistant prostate cancer. Our review provides an update in the development of several novel agents targeting the AR signalling pathway now in clinical testing, as well as review novel therapies in development with distinct mechanisms of action showing promising preclinical activity. Despite undergoing local therapy with curative intent, 20-30% of patients with prostate cancer will ultimately development metastatic disease, leading to morbidity and mortality. Androgen-deprivation therapy (ADT) for men with metastatic prostate cancer results in transient clinical benefit, but ultimately, cancers progress despite castrate levels of serum testosterone, a clinical state classically referred to as 'hormone refractory' disease. In this review, we examine mechanisms of resistance to ADT that have redefined our understanding of the more appropriately termed 'castration resistant' disease, and have paved the way for a new generation of therapeutics targeting the androgen signalling axis in advanced prostate cancer.

Original languageEnglish
Pages (from-to)1580-1588
Number of pages9
JournalBJU International
Issue number11
StatePublished - Dec 2012


  • androgen deprivation
  • androgen receptor
  • castration resistance
  • hormone refractory
  • novel endocrine therapy
  • prostate cancer


Dive into the research topics of 'Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC)'. Together they form a unique fingerprint.

Cite this